
Open Orphan swings into profit as it announces €6.7m contract win
Open Orphan has swung into profit for the first half of this year. It comes as the company announced that its subsidiary, Hvivo, has signed a £5.7m (€6.7m) contract with
Open Orphan has swung into profit for the first half of this year. It comes as the company announced that its subsidiary, Hvivo, has signed a £5.7m (€6.7m) contract with
UK-based pharmaceutical company, Open Orphan reported higher profit in its six-month financial statement. Revenue grew 242% to £21.9m compared to £6.4m for the same period last year. Growth was driven by
Open Orphan plc (LON:ORPH), a rapidly growing specialist clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced its unaudited interim
Respiratory Syncytial Virus, commonly referred to as RSV, is a respiratory virus that causes cold-like symptoms in the typical healthy adult, which can last on average for one week. However,
If you are going to catch covid-19, jokes Jacob Hopkins, a university student, the safest place to do it is in a hospital. So in March Mr Hopkins lay down on
From the early phases of development through marketing authorisation, regulatory interactions are essential to your progress and success. These exchanges will not only shape the advancement of your program, but
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that its interim results
Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has noted the
Jake Hopkins, a university student in the U.K., decided earlier this year to do something most people in the world have been trying to avoid: he volunteered to get Covid-19.